What's new, what's hot, what's timely? If you don't have time to search the Internet for
the latest developments that might impact your work environment, you just might find some
of that information in this Capsule column. Please e-mail any comments, suggestions, or
insights to Sherry Bohn at sbohn1@umd.edu or
Robert Rasmussen at robert_rasmussen@dfci.harvard.edu.
References
1.
LingL, SchneiderT, PeoplesA, SpoeringA, EngelsI, ConlonB. A new antibiotic kills pathogens without detectable
resistance. Nature. 2015; 517:455–9.
2.
AltenburgA. Modified vaccinia virus Ankara (MVA) as production platform for vaccines
against influenza and other viral respiratory diseases. Viruses. 2014; 6(7):2735–61.
3.
KreijtzJ. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based
influenza A H5N1 vaccine: A randomised, double-blind phase 1/2a clinical
trial. The Lancet Infectious Diseases. 2014; 14(12):1196–207.
